Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
Mar 01, 2017 12:00 pm UTC| Business
Fourth quarter and Full Year 2016 Auryxia® (ferric citrate) net U.S. product sales of $8.2 million and $27.2 million, respectively Early 2017 Auryxia prescription demand showing positive momentum and outperformed overall...
The 2017 FOX Wealth Advisor Forum Helps Wealth Advisors in “Managing Disruption”
Mar 01, 2017 12:00 pm UTC| Business
CHICAGO, March 01, 2017 -- On May 2-4, Family Office Exchange (FOX) will share its latest insights into the needs of the world's most financially successful families and their preferred ways of working with their...
Calithera Biosciences to Present at Cowen and Company 37th Annual Health Care Conference
Mar 01, 2017 12:00 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., March 01, 2017 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor...
Tucows Announces $40 Million Stock Buyback Program
Mar 01, 2017 12:00 pm UTC| Business
TORONTO, March 01, 2017 -- Tucows Inc. (NASDAQ:TCX) (TSX:TC) today announced that its Board of Directors has approved a stock buyback program to repurchase from time to time up to $40 million of its common stock in the...
IRADIMED CORPORATION to Present at 29th Annual Roth Conference
Mar 01, 2017 12:00 pm UTC| Business
WINTER SPRINGS, Fla., March 01, 2017 -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that Roger Susi, President and Chief Executive Officer and Chris Scott, Chief Financial Officer, will present at the 29th...
Mar 01, 2017 12:00 pm UTC| Business
SAINT-GENIS-POUILLY, France, March 01, 2017 -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that its...
Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
Mar 01, 2017 12:00 pm UTC| Business
DEVON, Pa., March 01, 2017 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today...
U.S. Appeals Court Allows Trump Administration to Enforce Medicaid Funding Ban on Planned Parenthood